Imaging flow cytometry for automated detection of hypoxia‐induced erythrocyte shape change in sickle cell disease
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
In preclinical and early phase pharmacologic trials in sickle cell disease, the percentage of sickled erythrocytes after deoxygenation, an ex vivo functional sickling assay, has been used as a measure of a patient's disease outcome. We developed a new sickle imaging flow cytometry assay (SIFCA) and investigated its application. To perform the SIFCA, peripheral blood was diluted, deoxygenated (2% oxygen) for 2 hr, fixed, and analyzed using imaging flow cytometry. We developed a software algorithm that correctly classified investigator tagged “sickled” and “normal” erythrocyte morphology with a sensitivity of 100% and a specificity of 99.1%. The percentage of sickled cells as measured by SIFCA correlated strongly with the percentage of sickle cell anemia blood in experimentally admixed samples (R = 0.98,P ≤ 0.001), negatively with fetal hemoglobin (HbF) levels (R = −0.558,P = 0.027), negatively with pH (R = −0.688,P = 0.026), negatively with pretreatment with the antisickling agent, Aes‐103 (5‐hydroxymethyl‐2‐furfural) (R = −0.766,P = 0.002), and positively with the presence of long intracellular fibers as visualized by transmission electron microscopy (R = 0.799,P = 0.002). This study shows proof of principle that the automated, operator‐independent SIFCA is associated with predictable physiologic and clinical parameters and is altered by the putative antisickling agent, Aes‐103. SIFCA is a new method that may be useful in sickle cell drug development. Am. J. Hematol. 89:598–603, 2014. © 2014 Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fetal hemoglobin in sickle cell anemia
Akinsheye, I., Alsultan, A., Solovieff, N., Ngo, D., Baldwin, C. T., Sebastiani, P., Chui, D. H. K., & Steinberg, M. H. (2011) · Blood · doi:10.1182/blood-2011-03-325258 · Cited by 553
Levels of Fetal Hemoglobin Necessary for Treatment of Sickle Cell Disease
Noguchi, C. T., Rodgers, G. P., Serjeant, G., & Schechter, A. N. (1988) · New England Journal of Medicine · doi:10.1056/nejm198801143180207 · Cited by 222 · cited 1×
“It is well accepted that the mechanism of action of hydroxyurea is to increase HbF levels and hence reduce the rate of HbS polymer formation in sickle erythrocytes [7,8].”
BackgroundBrittenham, G., Schechter, A., & Noguchi, C. (1985) · Blood · doi:10.1182/blood.v65.1.183.183 · Cited by 197
Lin, T., Kwak, Y. H., Sammy, F., He, P., Thundivalappil, S., Sun, G., Chao, W., & Warren, H. S. (2010) · The Journal of Infectious Diseases · doi:10.1086/654929 · Cited by 91 · cited 1×
“The pathophysiologic basis of SCD lies in the tendency of HbS to polymerize on deoxygenation [3].”
Background
Cited by
Intravascular hemolysis and the pathophysiology of sickle cell disease
Kato, G. J., Steinberg, M. H., & Gladwin, M. T. (2017) · Journal of Clinical Investigation · doi:10.1172/jci89741 · Cited by 748
Self-citationTreating sickle cell disease by targeting HbS polymerization
Eaton, W. A., & Bunn, H. F. (2017) · Blood · doi:10.1182/blood-2017-02-765891 · Cited by 255
Real-Time Sickle Cell Anemia Diagnosis Based Hardware Accelerator
Fadhel, M. A., Al-Shamma, O., Alzubaidi, L., & Oleiwi, S. R. (2020) · Communications in Computer and Information Science · doi:10.1007/978-3-030-55340-1_14 · Cited by 5
Metadata
- Authors
- van Beers, E. J., Samsel, L., Mendelsohn, L., Saiyed, R., Fertrin, K. Y., Brantner, C. A., Daniels, M. P., Nichols, J., McCoy, J. P., & Kato, G. J.
- Venue
- American Journal of Hematology
- Publisher
- Wiley
- Published
- 2014-04-12
- Volume
- 89
- Issue
- 6
- Pages
- 598-603
- ISSN
- 0361-8609 (ISSN-L)
- 1096-8652
- OpenAlex
- W1531256486
- Cited by
- 66
- References
- 4
- FWCI
- 3.00
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.